Laboratory of Molecular Epidemiology for Infectious Agents, Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan.
Microb Drug Resist. 2013 Aug;19(4):308-15. doi: 10.1089/mdr.2012.0180. Epub 2013 Mar 12.
In Japan, the heptavalent pneumococcal conjugate vaccine (PCV7) has been introduced on a voluntary basis since February 2010, and official financial support for children under 5 years started in November 2010. The impact of PCV7 on invasive pneumococcal diseases (IPD) in children is unknown. There are 340 medical institutions that actively participated in our surveillance project throughout Japan. We collected 252 strains from patients with IPD in 2006 (pre-PCV7), 280 strains in 2010 (under 10% immunization achieved), and 128 strains in 2011 (50% to 60% immunization). Serotypes and penicillin-resistance genotypes (g) were compared between these years. Multilocus sequence typing was also carried out on these strains. Due to the official promotion, IPD significantly decreased in 2011 (p<0.001). In particular, meningitis and sepsis caused by vaccine type (VT) strains declined (p=0.033, p<0.001). In less than 2 years, among nonvaccine types (NVT), 15A and 22F increased in 2011 (p=0.015, p=0.015). Coverage by PCV7 decreased from 71.8% in 2006 to 51.6% in 2011. Sequence-type diversities accompanied by evolution to gPRSP occurred in both VT and NVT strains. Reduction of IPD caused by VT strains was accomplished, but a rapid increase of NVT raises concern about a future decrease in the efficacy of PCV7.
在日本,自 2010 年 2 月以来,已在自愿基础上引入了七价肺炎球菌结合疫苗(PCV7),2010 年 11 月开始为 5 岁以下儿童提供官方财政支持。PCV7 对儿童侵袭性肺炎球菌病(IPD)的影响尚不清楚。全日本共有 340 家医疗机构积极参与了我们的监测项目。我们收集了 2006 年(PCV7 之前)252 株来自 IPD 患者的菌株,2010 年 280 株(接种率达到 10%),2011 年 128 株(接种率达到 50%至 60%)。比较了这些年份的血清型和青霉素耐药基因型(g)。还对这些菌株进行了多位点序列分型。由于官方推广,2011 年 IPD 显著减少(p<0.001)。特别是疫苗型(VT)菌株引起的脑膜炎和败血症减少(p=0.033,p<0.001)。在不到 2 年的时间里,2011 年非疫苗型(NVT)15A 和 22F 增加(p=0.015,p=0.015)。PCV7 的覆盖率从 2006 年的 71.8%降至 2011 年的 51.6%。VT 和 NVT 菌株的序列型多样性伴随着 gPRSP 的进化。VT 菌株引起的 IPD 减少已完成,但 NVT 的快速增加引起对 PCV7 未来效力下降的担忧。